$POST

2 Profitable Stocks with Exciting Potential and 1 We Find Risky

Post (POST) is flagged for potential decline due to projected sales drop, low gross margin, and poor capital returns. Terex (TEX) and Amgen (AMGN) are highlighted for growth potential, with TEX showing strong revenue growth and AMGN demonstrating high returns on capital. POST trades at 10.4x forward P/E, TEX at 9.8x, and AMGN at 18x.

Original reporting
Published Oct 1, 2026, 4:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 8:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
2 Profitable Stocks with Exciting Potential and 1 We Find Risky — source image
Decision brief

The 30-second read

$POSTBearishLow
01

Why it matters

The piece provides no fresh corporate events; it merely restates existing metrics and forward‑looking statements.

02

Market read

Low relevance; the article is a generic stock‑watch list without new data.

03

What to watch

Terex's growth could be cyclical; Amgen faces patent expiration risks not discussed.

Relevance 4/10Novelty 2/10Timing: none

Background

A promotional article from StockStory offering opinionated stock picks without new corporate disclosures.

Company-level read

Ticker impact

$POSTBearishMedium confidence
Context

The article recommends selling Post (POST) citing projected 5.9% sales decline and low margins.

Expected impact

likely downside as investors reassess growth prospects

Evidence & confidence

The piece flags a sales contraction and margin weakness, which could prompt sell‑offs.

$TEXBullishMedium confidence
Context

The article flags Terex (TEX) as a watch with projected 27.6% revenue growth and rising free cash flow.

Expected impact

possible rally if growth expectations are priced in

Evidence & confidence

High projected revenue growth and cash flow improvements suggest favorable fundamentals.

$AMGNBullishMedium confidence
Context

The article highlights Amgen (AMGN) as a buy candidate, noting its large revenue base and strong free cash flow.

Expected impact

could see buying pressure if investors act on the favorable fundamentals

Evidence & confidence

Emphasis on scale and cash flow may encourage investors to add positions.

Market effects

Highlights profitability concerns in packaged foods and growth prospects in industrial equipment and biotech.

U.S. equities may see modest sector rotation based on the mixed outlooks.

Limited; the commentary is U.S.-focused and does not affect broader macro trends.

Counterpoint

Post's margins may improve if it pivots to higher‑margin product lines, contrary to the sell recommendation.

Key entities

  • Post Holdings

    Packaged food company recommended for sale.

  • Terex Corporation

    Industrial equipment maker highlighted as a watch.

  • Amgen Inc.

    Biotech firm presented as a buy.

Related articles

$AZNHigh

Tezepelumab sustains ‘clinical benefit’ for EoE remission, dysphagia relief at 52 weeks

AstraZeneca and Amgen's tezepelumab showed significant improvement in histologic remission and dysphagia symptoms for eosinophilic esophagitis patients at 24 and 52 weeks, outperforming placebo. The phase 3 study enrolled 365 participants, with both 210 mg and 420 mg doses showing sustained benefits. Tezepelumab was well tolerated, with similar adverse event rates to placebo.

$AZNHigh

AstraZeneca And Amgen Report Positive Phase III CROSSING Trial Results For TEZSPIRE In Eosinophilic Esophagitis

AstraZeneca and Amgen's TEZSPIRE showed significant improvements in histologic remission and dysphagia symptoms in eosinophilic esophagitis patients at week 24, with sustained results through week 52. The trial, presented at UEGW 2026, reported 64.8% and 68.9% remission rates for 210mg and 420mg doses, respectively, vs. 3.5% for placebo. TEZSPIRE also reduced dysphagia symptoms and improved endoscopic features. The drug is approved for severe asthma and CRSwNP.

$SMCIHigh

Wall Street Futures Rise as Corporate Earnings Support Technology Stocks: Dow Jones, S&P, Nasdaq

US stock index futures rose on Wednesday, with tech stocks expected to lead gains. SpaceX (SPCX) shares surged 8.8% after beating earnings estimates, while Super Micro Computer (SMCI) gained 12.2% on raised revenue outlook. Netflix (NFLX) fell 6.8% and AT&T (T) dropped 5% despite strong earnings. Investors await results from Tesla (TSLA), Meta (META), and IBM (IBM). Dow, S&P 500, and Nasdaq showed mixed performance on Tuesday.

$AMGNMed

Amgen and AstraZeneca report positive Phase III results for Tezspire in EoE

Amgen and AstraZeneca reported positive Phase III trial results for Tezspire in treating eosinophilic oesophagitis (EoE). At week 52, 63.3–67.8% of patients achieved histologic remission, compared to 5.4% on placebo. The drug also reduced dysphagia symptoms and showed endoscopic remission in 29.5-34.4% of patients. Tezspire is already approved for severe asthma and chronic rhinosinusitis, and this new indication could expand its market potential.